



ESPERITE's shareholders approved the external financing of up to EUR 13 million.

Reports On Extraordinary General Meeting Of Shareholders

Zutphen, The Netherlands – 24 April 2017

Esperite N.V. (Euronext: ESP, "**Esperite**") announces that at its Extraordinary General Meeting of shareholders ("**EGM**"), held on Friday 21 April 2017, all proposals were unanimously approved.

Shareholders unanimously approve the issuance of further tranches of convertible notes (with share subscription warrants attached) to European Select Growth Opportunities Fund

This means that Esperite will now be able to proceed with the recently announced external financing of up to EUR 13 million and the issuance of further tranches of convertible notes (with share subscription warrants attached) to European Select Growth Opportunities Fund.

As announced previously, the proceeds shall be used to support Esperite's commercial activities and development of innovative technologies in the field of genetics for Genoma and regenerative medicine for Cryo-Save and Cell Factory.

The presentation slides from today's EGM can be downloaded from Esperite's website (www.esperite.com).

About ESPERITE N.V.

ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.